Get the Stockscreener App
3.34
0.00%
0.00
After Hours:
3.30
-0.04
-1.20%
Gossamer Bio Inc stock is traded at $3.34, with a volume of 1.14M.
It is up +0.00% in the last 24 hours and up +40.34% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$3.34
Open:
$3.325
24h Volume:
1.14M
Relative Volume:
0.31
Market Cap:
$773.06M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-2.5113
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
+9.15%
1M Performance:
+40.34%
6M Performance:
+187.93%
1Y Performance:
+375.99%
1-Day Range:
$3.25
$3.40
1-Week Range:
$2.995
$3.40
52-Week Range:
$0.6666
$3.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
3.34 | 773.06M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
How Recent Developments Are Shaping the Gossamer Bio Investment Story - Yahoo Finance
Gossamer Bio, Inc.'s (NASDAQ:GOSS) 28% Share Price Surge Not Quite Adding Up - simplywall.st
Gossamer Bio to Participate in Upcoming December 2025 Investor Conferences - BioSpace
Gossamer Bio to Participate in Upcoming Investor Conferences - Enidnews.com
GOSS News Today | Why did Gossamer Bio stock go down today? - MarketBeat
How Gossamer Bio Inc. (4GB) stock reacts to fiscal policiesWeekly Trend Summary & Consistent Growth Equity Picks - newser.com
How Gossamer Bio Inc. (4GB) stock moves in volatile trading sessionsMarket Risk Analysis & Stock Portfolio Risk Management - newser.com
What downside risks could hit Gossamer Bio Inc. (4GB) stock2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Volume spikes in Gossamer Bio Inc. stock – what they meanPortfolio Risk Summary & Accurate Trade Setup Notifications - newser.com
What RSI levels show for Gossamer Bio Inc. (4GB) stockPortfolio Gains Report & Fast Entry Momentum Trade Alerts - newser.com
Strategies to average down on Gossamer Bio Inc.2025 Trading Recap & Long Hold Capital Preservation Tips - newser.com
Will Gossamer Bio Inc. stock benefit from sector rotationJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com
Why Gossamer Bio Inc. (4GB) stock could outperform next yearMarket Sentiment Report & Entry Point Confirmation Alerts - newser.com
Is now a turning point for Gossamer Bio Inc.July 2025 Market Mood & Real-Time Stock Movement Alerts - newser.com
Is Gossamer Bio Inc. stock near bottom after declineJuly 2025 Pullbacks & Safe Entry Point Identification - newser.com
Ranking Gossamer Bio Inc. among high performing stocks via toolsQuarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Why retail investors favor Gossamer Bio Inc. stockTreasury Yields & Advanced Swing Trade Entry Alerts - newser.com
Why Gossamer Bio Inc. stock remains undervalued2025 Risk Factors & Reliable Momentum Entry Alerts - newser.com
Why millennials buy Gossamer Bio Inc. (4GB) stockMarket Activity Recap & Community Verified Watchlist Alerts - newser.com
What valuation multiples suggest for Gossamer Bio Inc. stockBuy Signal & Community Verified Watchlist Alerts - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected - 富途牛牛
How to use Fibonacci retracement on Gossamer Bio Inc.Market Growth Summary & Real-Time Sentiment Analysis - newser.com
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):